oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciencesoncotomsk-53Research ArticleОБЗОРЫREVIEWSЭКСПЕРИМЕНТАЛЬНЫЕ И КЛИНИЧЕСКИЕ ПОДХОДЫ К РАДИОИММУНОТЕРАПИИ В ОНКОЛОГИИExperimental and clinical approaches to a radioimmunotherapy in oАбакушинаЕ. В.AbakushinaE. V.

249036, Калужская обл., г. Обнинск, ул. Королёва, 4

4, Koroleva St., 249036-Obninsk, Kaluga region

abakushina@mail.ruАбакушинД. Н.AbakushinD. N.abakushina@mail.ruАнохинЮ. Н.AnohinJu. N.

249036, Калужская обл., г. Обнинск, ул. Королёва, 4

4, Koroleva St., 249036-Obninsk, Kaluga region

abakushina@mail.ruФГБУ «Медицинский радиологический научный центр» Минздрава России, г. Обнинск Обнинский институт атомной энергетики – филиал ФГАОУ ВПО «Национальный исследовательский ядерный университет» «МИФИ», г. ОбнинскРоссияMedical radiological research center Ministry of Health of Russia, Obninsk Obninsk Institute for Nuclear Power Engineering of the National Research Nuclear University MEPhI, ObninskRussian FederationООО «Клиника № 1», г. ОбнинскРоссияMedical center «Сlinic № 1», ObninskRussian FederationОбнинский институт атомной энергетики – филиал ФГАОУ ВПО «Национальный исследовательский ядерный университет» «МИФИ», г. ОбнинскРоссияObninsk Institute for Nuclear Power Engineering of the National Research Nuclear University MEPhI, ObninskRussian Federation201411022016035664Copyright © Абакушина Е.В., Абакушин Д.Н., Анохин Ю.Н., 20162016Абакушина Е.В., Абакушин Д.Н., Анохин Ю.Н.Abakushina E.V., Abakushin D.N., Anohin J.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/53

Достижения молекулярной ядерной медицины широко применяются для диагностики и терапии заболеваний. Для радиоиммунодиагностики и радиоиммунотерапии (РИТ) используют антитела, конъюгированные с диагностическими или терапевтическими радионуклидами. Наиболее часто для РИТ используют моноклональные антитела (мАТ) против опухолеассоциированных антигенов, меченные альфа- или бета-излучающими радионуклидами. Применяя эту технологию, были достигнуты положительные результаты лечения лимфопролиферативных заболеваний. Менее чувствительными к РИТ оказались солидные опухоли. Считается, что РИТ больше подходит для лечения микроскопических образований и минимальной остаточной болезни благодаря тому, что меченные радионуклидами мАТ доставляют необходимую дозу радиации для уничтожения опухоли. Несмотря на некоторые успехи РИТ, продолжается поиск новых наиболее перспективных и значимых мишеней для радиоиммунодиагностики и РИТ. Для достижения этой цели первоначально требуется проведение экспериментов по изучению биодоступности и терапевтической эффективности меченых мАТ на моделях с использованием клеточных линий и лабораторных животных.

Molecular nuclear medicine plays an important role in the diagnosis and therapy of cancer. Radioimmunodetection and radioimmunotherapy (RIT) involve the use of antibodies conjugated with diagnostic or therapeutic radionuclides, respectively. More often for RIT use the monoclonal antibodies against tumor-associated antigens, radiolabeled with alpha or beta-emitters. Encouraging results have been achieved with this technology in the management of hematologic malignancies. On the contrary, solid tumors have been less responsive. Radioimmunotherapy therefore is considered more suitable for the treatment of microscopic or minimal residual disease, allowing radiolabeled monoclonal antibodies to achieve uptake in tumors high enough to result in tumoricidal radiation doses. Despite these encouraging results, new potential target for radioimmunodetection and RIT should be found. For this purpose, a series of experiments will be performing to investigate the biodistribution and the therapeutic efficacy of radiolabeled monoclonal antibodies in cell culture and animal models.

радиоиммунотерапиязлокачественные новообразованиямоноклональные антителаопухолеассоциированные антигенырадиоизотопradioimmunotherapymalignant diseasesmonoclonal antibodiestumor-associated antigensradionuclideReferencesАбакушин Д.Н., Абакушина Е.В., Анохин Ю.Н. Поиск новых мишеней для радиоиммунотерапии онкологических заболеваний // Вопросы онкологии. 2013. Т. 59, № 3. Прил. № 3. T. III. С. 1150.Abakushin D.N., Abakushina E.V., Anohin Ju.N. Search of new targets for a radio immunotherapy of oncological diseases // Voprosy onkologii. 2013. T. 59, № 3. Pril. № 3. T. III. P. 1150. [in Russian]Абакушина Е.В., Кузьмина Е.Г. Стресс-индуцированные молекулы MICA/B и их роль в развитии онкологических заболеваний // Молекулярная медицина. 2012. № 4. С. 16–20.Abakushina E.V., Kuz’mina E.G. The stress-induced molecules of MICA/B and their role in development of oncological diseases // Molekuljarnaja medicina. 2012. № 4. P. 16-20. [in Russian]Анохин Ю.Н., Норец Т.А., Деденков А.Н. Моноклональные антитела в радионуклидной диагностике и терапии опухолевых заболеваний // Медицинская радиология. 1985. № 6. С. 72–78.Anohin Ju.N., Norec T.A., Dedenkov A.N. Monoclonal antibodies in radio nuclide diagnostics and therapy of cancer diseases // Medicinskaja Radiologija. 1986. №6. С. 72–78. [in Russian]Анохин Ю.Н., Норец Т.А., Петрова Г.А., Ендолов В.В., Трофимова М.В., Новиков В.В. Избирательное накопление меченных 131-йодом моноклональных антител ИКО-1 в ткани мышиного лимфолейкоза L-1210 // Медицинская радиология. 1988. № 1. С. 31–33.Anohin Ju.N., Norec T.A., Petrova G.A., Endolov V.V., Trofimova M.V., Novikov V.V. Opportunity in vivo radionuclide diagnostics of hematologic tumors by means of marked monoclonal antibodies // Medicinskaja Radiologija. 1988. № 1. С. 31–33. [in Russian]Анохин Ю.Н. Использование нанотехнологий и наноматериалов для визуализации и терапии злокачественных опухолей // Фундаментальные проблемы науки. М.: НИЯУ МИФИ, 2010. Т. 3. С. 221–224.Anohin Ju.N. The nanotechnologies and nanomaterials for visualization and therapy of malignant tumors // Fundamentalnije problemy nauki. M., 2010. Vol. 3. P. 221–224. [in Russian]Глинка Е.М., Эдельвейс Э.Ф., Деев С.М. Эукариотические экспрессирующие векторы и иммуноконъюгаты для терапии рака // Биохимия. 2006. Т. 71, № 6. С. 742–753.Glinka E.M., Jedel’vejs Je.F., Deev S.M. The expressing vectors of eukaryot and immunoconjugates for cancer therapy // Biohimija. 2006. Т. 71, № 6. P. 742–753. [in Russian]Деев С.М., Лебеденко Е.Н. Инженерия антител: молекулярный конструктор на основе модуля барназа-барстар // Биоорганическая химия. 2009. Т. 35, № 6. С. 761–778.Deev S.M., Lebedenko E.N. Engineering of antibodies: the molecular designer on the basis of the module barnaza-barstar // Bioorganicheskaja himija. 2009. Vol. 71 (6). P. 761–778. [in Russian]Коваленко Е.И., Абакушина Е.В., Клинкова А.В., Кузьмина Е.Г., Каневский Л.М. Иммунорегуляторные молекулы MICA в сыворотке крови онкологических больных // Злокачественные опухоли. 2012. Т. 2, № 2. С. 167.Kovalenko E.I., Abakushina E.V., Klinkova A.V., Kuz’mina E.G., Kanevskij L.M. Immunoregulatory molecules of MICA in serum of blood of oncological patients // Zlokachestvennye opuholi. 2012. Т. 2, № 2. P. 167. [in Russian]Моисеенко В.М., Данилов А.О., Балдуева И.А., Данилова А.Б., Фахрутдинова О.Л. Иммунохимический анализ продукции MIC A опухолевыми клетками, in vitro и in vivo в контексте создания и применения противоопухолевых вакцин // Вопросы онкологии. 2010. № 5. С. 576–582.Moiseenko V.M., Danilov A.O., Baldueva I.A., Danilova A.B., Fahrutdinova O.L. The immunochemical analysis of tumor cells production of MICA, in vitro and in vivo in a context of reparation and application of cancer vaccines // Voprosy onkologii. 2010. № 5. P. 576–582. [in Russian]Сморызанова О.А., Новикова И.С., Скворцов В.Г., Подгородниченко В.К., Петриев В.М. Перспективы использования металлотионеина в качестве хелатирующего агента для разработки радиофармпрепаратов на основе 213Bi // Вопросы биологической, медицинской и фармацевтической химии. 2010. № 1. С. 44–49.Smoryzanova O.A., Novikova I.S., Skvorcov V.G., Podgorodnichenko V.K., Petriev V.M. Prospects for the use of metallothionein as a chelating agent for the development of radiopharmaceuticals based on 213Bi // Voprosy biologicheskoj, medicinskoj ™ farmacevticheskoj himii. 2010. № 1. С. 44–49. [in Russian]A Prospective non-randomized study of 131I-L19SIP radioimmunotherapy in combination with whole brain radiation therapy in patients with multiple brain metastases from solid tumors. http://clinicaltrials.gov/ ct2/show/NCT01125085A Prospective non-randomized study of 131I-L19SIP radioimmunotherapy in combination with whole brain radiation therapy in patients with multiple brain metastases from solid tumors. http://clinicaltrials.gov/ ct2/show/NCT01125085Adams G.P., Weiner L.M. Monoclonal antibody therapy of cancer // Nat. Biotechnol. 2005. Vol. 23 (9). P. 1147–1157.Adams G.P., Weiner L.M. Monoclonal antibody therapy of cancer // Nat. Biotechnol. 2005. Vol. 23 (9). P. 1147–1157.Balandin T.G., Edelweiss E., Andronova N.V., Treshalina E.M., Sapozhnikov A.M., Deyev S.M. Antitumor activity and toxicity of antiHER2 immunoRNase scFv 4D5-dibarnase in mice bearing human breast cancer xenografts // // Invest. New Drugs. 2009. Vol. 29 (1). P. 22–32. doi: 10.1007/s10637-009-9329-2.Balandin T.G., Edelweiss E., Andronova N.V., Treshalina E.M., Sapozhnikov A.M., Deyev S.M. Antitumor activity and toxicity of anti-HER2 immunoRNase scFv 4D5-dibarnase in mice bearing human breast cancer xenografts // Invest. New Drugs. 2009. Vol. 29 (1). P. 22–32. doi: 10.1007/ s10637-009-9329-2.Behr T.M., Sharkey R.M., Juweid M.E., Dunn R.M., Ying Z., Zhang C.H., Siegel J.A., Goldenberg D.M. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies // J. Nucl. Med. 1997. Vol. 38. P. 409–418.Behr T.M., Sharkey R.M., Juweid M.E., Dunn R.M., Ying Z., Zhang C.H., Siegel J.A., Goldenberg D.M. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with antiCEA and antimucin monoclonal antibodies // J. Nucl. Med. 1997. Vol. 38. P. 409–418.Behr T.M., Blumenthal R.D., Memtsoudis S., Sharkey R.M., Gratz S., Becker W., Goldenberg D.M. Cure of metastatic human colonic cancer in mice with radiolabeled monoclonal antibody fragments // Clin. Cancer Res. 2000. Vol. 6. P. 4900–4907.Behr T.M., Blumenthal R.D., Memtsoudis S., Sharkey R.M., Gratz S., Becker W., Goldenberg D.M. Cure of metastatic human colonic cancer in mice with radiolabeled monoclonal antibody fragments // Clin. Cancer Res. 2000. Vol. 6. P. 4900–4907.Bieker R., Kessler T., Schwoppe C., Padrу T., Persigehl T., Bremer C., Dreischalück J., Kolkmeyer A., Heindel W., Mesters R.M., Berdel W.E. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience // Blood. 2009. Vol. 113 (20). P. 5019–5027. doi: 10.1182/blood-2008-04-150318.Bieker R., Kessler T., Schwoppe C., Padrу T., Persigehl T., Bremer C., Dreischalück J., Kolkmeyer A., Heindel W., Mesters R.M., Berdel W.E. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience // Blood. 2009. Vol. 113 (20). P. 5019–5027. doi: 10.1182/blood-2008-04-150318.Burvenich I., Schoonooghe S., Cornelissen B., Blanckaert P., Coene E., Cuvelier C., Mertens N., Slegers G. In vitro and In vivo targeting properties of Iodine-123- or Iodine-131 labeled monoclonal antibody 14C5 in a non small cell lung cancer and colon carcinoma model // Clin. Cancer Res. 2005. Vol. 11. P. 7288–7296.Burvenich I., Schoonooghe S., Cornelissen B., Blanckaert P., Coene E., Cuvelier C., Mertens N., Slegers G. In vitro and In vivo targeting properties of Iodine-123- or Iodine-131 labeled monoclonal antibody 14C5 in a non small cell lung cancer and colon carcinoma model // Clin. Cancer Res. 2005. Vol. 11. P. 7288–7296.Cheson B.D. Radioimmunotherapy of non-Hodgkin lymphomas // Blood. 2003. Vol. 101. P. 391–398.Cheson B.D. Radioimmunotherapy of non-Hodgkin lymphomas // Blood. 2003. Vol. 101. P. 391–398.Clarke K., Lee F.T., Brechbiel M.W., Smyth F.E., Old L.J., Scott A.M. In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice // Cancer Res. 2000. Vol. 60. P. 4804–4811.Clarke K., Lee F.T., Brechbiel M.W., Smyth F.E., Old L.J., Scott A.M. In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice // Cancer Res. 2000. Vol. 60. P. 4804–4811.Conti P.S.,White C., Pieslor P., Molina A., Aussie J., Foster P. The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a Zevalin Imaging Registry // J. Nucl. Med. 2005. Vol. 46 (11). P. 1812–1818.Conti P.S.,White C., Pieslor P., Molina A., Aussie J., Foster P. The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a Zevalin Imaging Registry // J. Nucl. Med. 2005. Vol. 46 (11). P. 1812–1818.Dadachova E., Casadevall A. Renaissance of targeting molecules for melanoma // Cancer Biother. Radiopharm. 2006. Vol. 21 (6). P. 545–552.Dadachova E., Casadevall A. Renaissance of targeting molecules for melanoma // Cancer Biother. Radiopharm. 2006. Vol. 21 (6). P. 545–552.De Potter C.R., Schelfhout A.M., De Smet F.H., van Damme S., de Ridder L., Dhont E., van Emmelo J. A monoclonal antibody directed against a human cell membrane antigen prevents cell substrate adhesion and tumor invasion // Am. J. Pathol. 1994. Vol. 144. P. 95–103.De Potter C.R., Schelfhout A.M., De Smet F.H., Van Damme S., de Ridder L., Dhont E., van Emmelo J. A monoclonal antibody directed against a human cell membrane antigen prevents cell substrate adhesion and tumor invasion // Am. J. Pathol. 1994. Vol. 144. P. 95–103.Deyev S.M., Waibel R., Lebedenko E.N., Schubiger A.P., Plückthun A. Design of multivalent complexes using the barnasebarstar module // Nat. Biotechnol. 2003. Vol. 21. P. 1486–1492.Deyev S.M., Waibel R., Lebedenko E.N., Schubiger A.P., Plückthun A. Design of multivalent complexes using the barnasebarstar module // Nat. Biotechnol. 2003. Vol. 21. P. 1486–1492.Goldenberg D.M., Rossi E.A., Sharkey R.M., McBride W.J, Chang C.H. Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting // J. Nucl. Med. 2008. Vol. 49 (1). P.158–163.Goldenberg D.M., Rossi E.A., Sharkey R.M., McBride W.J, Chang C.H. Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting // J. Nucl. Med. 2008. Vol. 49 (1). P.158–163.Grillo-Lopez A.J. Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma // Expert Rev. Anticancer Ther. 2002. Vol. 2. P. 485–493.Grillo-Lopez A.J. Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma // Expert Rev. Anticancer Ther. 2002. Vol. 2. P. 485–493.Groh V., Rhinehart R., Secrist H., Bauer S., Grabstein K.H., Spies T. Broad tumor-associated expression and recognition by tumorderived gamma delta T cells of MICA and MICB // Proc. Natl. Acad. Sci. USA. 1999. Vol. 96. P. 6879–6884.Groh V., Rhinehart R., Secrist H., Bauer S., Grabstein K.H., Spies T. Broad tumor-associated expression and recognition by tumorderived gamma delta T cells of MICA and MICB // Proc. Natl. Acad. Sci. USA. 1999. Vol. 96. P. 6879–6884.Kaminski M.S., Estes J., Zasadny K.R., Francis I.R., Ross C.W., Tuck M., Regan D., Fisher S., Gutierrez J., Kroll S., Stagg R., Tidmarsh G., Wahl R.L. Radioimmunotherapy with iodide (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience // Blood. 2000. Vol. 96. P. 1259–1266.Kaminski M.S., Estes J., Zasadny K.R., Francis I.R., Ross C.W., Tuck M., Regan D., Fisher S., Gutierrez J., Kroll S., Stagg R., Tidmarsh G., Wahl R.L. Radioimmunotherapy with iodide (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience // Blood. 2000. Vol. 96. P. 1259–1266.Klein M., Shibli N., Friedmann N., Thornton G.B., Chisin R., Lotem M. Imaging of metastatic melanoma (MM) with a 188Rhenium (188Re)-labeled melanin binding antibody // J. Nucl. Med. 2008. Vol. 49. Suppl. 1. P. 52.Klein M., Shibli N., Friedmann N., Thornton G.B., Chisin R., Lotem M. Imaging of metastatic melanoma (MM) with a 188Rhenium (188Re)-labeled melanin binding antibody // J. Nucl. Med. 2008. Vol. 49. Suppl. 1. P. 52.Klein M., Lotem M., Peretz T., Zwas S.T., Mizrachi S., Liberman Y., Chisin R., Schachter J., Ron I.G., Iosilevsky G., Kennedy J.A., Revskaya E., de Kater A.W., Banaga E., Klutzaritz V., Friedmann N., Galun E., Denardo G.L., Denardo S.J., Casadevall A., Dadachova E., Thornton G.B. Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma // J. Skin Cancer. 2013; 2013: 828329. doi: 10.1155/2013/828329. Epub 2013. Jan 10.Klein M., Lotem M., Peretz T., Zwas S.T., Mizrachi S., Liberman Y., Chisin R., Schachter J., Ron I.G., Iosilevsky G., Kennedy J.A., Revskaya E., de Kater A.W., Banaga E., Klutzaritz V., Friedmann N., Galun E., Denardo G.L., Denardo S.J., Casadevall A., Dadachova E., Thornton G.B. Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma // J. Skin Cancer. 2013; 2013: 828329. doi: 10.1155/2013/828329. Epub 2013 Jan 10.Kobayashi H., Shirakawa K., Kawamoto S., Saga T., Sato N., Hiraga A., Watanabe I., Heike Y., Togashi K., Konishi J., Brechbiel M.W., Wakasugi H. Rapid accumulation and internalization of radiolabeled herceptinin aninflammatory breast cancer xenograft with vasculogenic mimicry predicted by the contrastenhanced dynamic MRI with the macromolecular contrast agent G6-(1B4M-Gd)(256) // Cancer Res. 2002. Vol. 62. P. 860–866.Kobayashi H., Shirakawa K., Kawamoto S., Saga T., Sato N., Hiraga A., Watanabe I., Heike Y., Togashi K., Konishi J., Brechbiel M.W., Wakasugi H. Rapid accumulation and internalization of radiolabeled herceptinin aninflammatory breast cancer xenograft with vasculogenic mimicry predicted by the contrastenhanced dynamic MRI with the macromolecular contrast agent G6-(1B4M-Gd)(256) // Cancer Res. 2002. Vol. 62. P. 860–866.Koppe M.J., Bleichrodt R.P., Soede A.C., Verhofstad A.A., Goldenberg D.M., Oyen W.J., Boerman O.C. Biodistribution and therapeutic efficacy of 125/131I-, 186Re-, 88/90Y-, or 177Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin // J. Nucl. Med. 2004. Vol. 45. P. 1224–1232.Koppe M.J., Bleichrodt R.P., Soede A.C., Verhofstad A.A., Goldenberg D.M., Oyen W.J., Boerman O.C. Biodistribution and therapeutic efficacy of 125/131I-, 186Re-, 88/90Y-, or 177Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin // J. Nucl. Med. 2004. Vol. 45. P. 1224–1232.Le Doussal J.M., Martin M., Gautherot E., Delaage M., Barbet J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity murine model of adult T-cell leukemia with the alpha-emitting radionuclide, for cell-bound antibody conjugate // J. Nucl. Med. 1989. Vol. 30. P. 1358–1366.Le Doussal J.M., Martin M., Gautherot E., Delaage M., Barbet J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity murine model of adult T-cell leukemia with thealpha-emitting radionuclide, for cell-bound antibody conjugate // J. Nucl. Med. 1989. Vol. 30. P. 1358–1366.Milenic D.E., Brady E.D., Brechbiel M.W. Antibody-targeted radiation cancer therapy // Nat. Rev. Drug Discov. 2004. Vol. 3 (6). P. 488–499.Milenic D.E., Brady E.D., Brechbiel M.W. Antibody-targeted radiation cancer therapy // Nat. Rev. Drug Discov. 2004. Vol. 3 (6). P. 488–499.Nielsen U.B., Adams G.P., Weiner L.M., Marks J.D. Targeting of bivalent anti-erbB2 antibody fragments to tumor cells is independent of the intrinsic antibody affinity // Cancer Res. 2000. Vol. 60. P. 6434–6440.Nielsen U.B., Adams G.P., Weiner L.M., Marks J.D. Targeting of bivalent anti-erbB2 antibody fragments to tumor cells is independent of the intrinsic antibody affinity // Cancer Res. 2000. Vol. 60. P. 6434–6440.Palumbo A., Hauler F., Dziunycz P., Schwager K., Soltermann A., Pretto F., Alonso C., Hofbauer G.F., Boyle R.W., Neri D. A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels // Br. J. Cancer. 2011. Vol. 104 (7). P. 1106–1115. doi: 10.1038/bjc.2011.78.Palumbo A., Hauler F., Dziunycz P.,Schwager K., Soltermann A., Pretto F., Alonso C., Hofbauer G.F., Boyle R.W., Neri D. A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels // Br. J. Cancer. 2011. Vol. 104 (7). P. 1106–1115. doi: 10.1038/bjc.2011.78.Phaeton R., Wang X.G., Einstein M.H., Goldberg G.L., Casadevall A., Dadachova E. The influence of proteasome inhibitor MG132, external radiation and unlabeled antibody on the tumor uptake and biodistribution of 188Re-labeled anti-E6 C1P5 antibody in cervical cancer in mice // Cancer. 2010. Vol. 15 (116). Suppl. 4. P. 1067–1074. doi: 10.1002/cncr.24794.Phaeton R., Wang X.G., Einstein M.H., Goldberg G.L., Casadevall A., Dadachova E. The influence of proteasome inhibitor MG132, external radiation and unlabeled antibody on the tumor uptake and biodistribution of 188Re-labeled anti-E6 C1P5 antibody in cervical cancer in mice // Cancer. 2010. Vol. 15 (116). Suppl. 4. P. 1067–1074. doi: 10.1002/cncr.24794.Revskaya E., Jongco A.M., Sellers R.S., Howell R.C., Koba W., Guimaraes A.J., Nosanchuk J.D., Casadevall A., Dadachova E. Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine // Clin. Cancer Res. 2009. Vol. 15 (7). P. 2373–2379. doi: 10.1158/1078-0432. CCR-08-2376.Revskaya E., Jongco A.M., Sellers R.S., Howell R.C., Koba W., Guimaraes A.J., Nosanchuk J.D., Casadevall A., Dadachova E. Radioimmunotherapy of experimental human metastatic melanoma with melaninbinding antibodies and in combination with dacarbazine // Clin. Cancer Res. 2009. Vol. 15 (7). P. 2373–2379. doi: 10.1158/1078-0432.CCR-08-2376.Serebrovskaya E.O., Edelweiss E.F., Stremovskiy O.A., Lukyanov K.A., Chudakov D.M., Deyev S.M. Targeting cancer cells by using an antireceptor antibody-photosensitizer fusion protein // Proc. Natl. Acad. Sci. USA. 2009. Vol. 106. P. 9221–9225. doi: 10.1073/ pnas.0904140106.Serebrovskaya E.O., Edelweiss E.F., Stremovskiy O.A., Lukyanov K.A., Chudakov D.M., Deyev S.M. Targeting cancer cells by using an antireceptor antibody-photosensitizer fusion protein // Proc. Natl. Acad. Sci. USA. 2009. Vol. 106. P. 9221–9225. doi: 10.1073/pnas.0904140106.Shimoni A., Avivi I., Rowe J.M., Yeshurun M., Levi I., Or R., Patachenko P., Avigdor A., Zwas T., Nagler A. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma // Cancer. 2012. Vol. 118 (19). P. 4706–4714. doi: 10.1002/cncr.27418.Shimoni A., Avivi I., Rowe J.M., Yeshurun M., Levi I., Or R., Patachenko P., Avigdor A., Zwas T., Nagler A. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma // Cancer. 2012. Vol. 118 (19). P. 4706–4714. doi: 10.1002/cncr.27418.Tomblyn M. Radioimmunotherapy for B-cell non-hodgkin lymphomas // Cancer Control. 2012. Vol. 19 (3). P. 196–203.Tomblyn M. Radioimmunotherapy for B-cell non-hodgkin lymphomas // Cancer Control. 2012. Vol. 19 (3). P. 196–203.Witzig 14 T.E. Zevalin (TM). Treatment of non-Hodgkin’s lymphoma // Drugs Future. 2002. Vol. 27. P. 563–568.Witzig 14 T.E. Zevalin ™. Treatment of non-Hodgkin’s lymphoma // Drugs Future. 2002. Vol. 27. P. 563–568.Wu A.M., Senter P.D. Arming antibodies: prospects and challenges for immunoconjugates // Nat. Biotechnol. 2005. Vol. 23 (9). P. 1137–1146.Wu A.M., Senter P.D. Arming antibodies: prospects and challenges for immunoconjugates // Nat. Biotechnol. 2005. Vol. 23 (9). P. 1137–1146.Zdobnova T.A., Stremovskiy O.A., Lebedenko E.N., Deyev S.M. Self-assembling complexes of quantum dots and scFv antibodies for cancer cell targeting and imaging // PLoS One. 2012. Vol. 7 (10). e48248. doi: 10.1371/journal.pone.0048248.Zdobnova T.A., Stremovskiy O.A., Lebedenko E.N., Deyev S.M. Self-assembling complexes of quantum dots and scFv antibodies for cancer cell targeting and imaging // PloS One. 2012. Vol. 7 (10). E48248. doi: 10.1371/journal.pone.0048248.Zhao X.Y., Liu H.L., Liu B., Willuda J., Siemeister G., Mahmoudi M., Dinter H. Tomoregulin Internalization Confers Selective Cytotoxicity of Immunotoxins on Prostate Cancer // Cells Transl. Oncol. 2008. Vol. 1. P. 102–109.Zhao X.Y., Liu H.L., Liu B., Willuda J., Siemeister G., Mahmoudi M., Dinter H. Tomoregulin Internalization Confers Selective Cytotoxicity of Immunotoxins on Prostate Cancer // Cells Transl. Oncol. 2008. Vol. 1. P. 102–109.

The authors declare that there are no conflicts of interest present.